Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  08/28/2019
 
Trade Name:  Harvoni
 
Generic Name or Proper Name (*):  ledipasvir and sofosbuvir
 
Indications Studied:  Treatment of pediatric patients 3 to less than 12 years, weighing at least 17 kg, with chronic hepatitis C virus (HCV)
 
Label Changes Summary:  *Expanded indication to pediatric patients 3 to 11 years; previously approved in pediatric patients 12 years and older. *Safety and efficacy have not been established in pediatric patients less than 3 years of age. *Adverse reactions were similar to those observed in adults. *Information on dosing, PK parameters, adverse reactions, clinical trial. *New dosage form.
 
BPCA(B) and PREA(P):  B,P
 
Sponsor:  Gilead Sciences, Inc.
 
Pediatric Exclusivity Granted Date:  07/23/2019
 
NNPS:  FALSE
 
Therapeutic Category:  Antiviral
 
-
-